EUVIMEDEUVIMED entdecken
Crossref

Influence of familial forms of inflammatory bowel disease on the use of immunosuppressants, biological agents, and surgery in the era of biological therapies. Results from the ENEIDA project

Carlos González-Muñoza iD, Margalida Calafat, Javier P Gisbert, Eva Iglesias, Miguel Mínguez, Beatriz Sicilia, Montserrat Aceituno, Fernando Gomollón, Xavier Calvet, Elena Ricart, Luisa De Castro, Montserrat Rivero und 39 weitere

Postgraduate Medical Journal · 2024

DOI: 10.1093/postmj/qgae076 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Postgraduate Medical Journal, 2024. Verfasst von Carlos González-Muñoza und 50 weiteren Autor:innen. Beteiligte Einrichtung: H. Santa Creu i Sant Pau (Gastroenterology Department, Barcelona, Spain). Hauptthemen laut MEDLINE: Immunosuppressive Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: AbbVie, Galápagos, Janssen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and aims Familial inflammatory bowel disease (IBD) history is a controversial prognostic factor in IBD. We aimed to evaluate the impact of a familial history of IBD on the use of medical and surgical treatments in the biological era.

Methods

Patients included in the prospectively maintained ENEIDA database and diagnosed with IBD after 2005 were included. Familial forms were defined as those cases with at least one first-degree relative diagnosed with IBD. Disease phenotype, the use of biological agents, or surgical treatments were the main outcomes.

Results

A total of 5263 patients [2627 Crohn’s disease (CD); 2636 ulcerative colitis (UC)] were included, with a median follow-up of 31 months. Of these, 507 (10%) corresponded to familial forms. No clinical differences were observed between familial and sporadic IBD forms except a lower age at IBD diagnosis and a higher rate of males in familial forms of UC. In CD, the proportions of patients treated with thiopurines (54.4% vs 46.7%; P = .015) and survival time free of thiopurines (P = .009) were lower in familial forms. No differences were found regarding the use of biological agents. Concerning surgery, a higher rate of intestinal resections was observed in sporadic CD (14.8% vs 9.9%, P = .027). No differences were observed in UC.

Conclusions

In the era of biological therapies, familial and sporadic forms of IBD show similar phenotypes and are managed medically in a similar way; whether these is due to lack of phenotypical differences or an effect of biological therapies is uncertain. What is already known on this topic: IBD’s etiopathogenesis points to an interaction between environmental and genetic factors, being familial history a controversial prognostic factor. Biological agents use and need for surgery regarding familial or sporadic forms of IBDs present conflicting results. What this study adds: Familial and sporadic forms of IBD have similar phenotypes and are managed medically and surgically in a similar way. How this study might affect research, practice or policy: Familial aggregation should not be considered a factor associated with more aggressive disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunosuppressive AgentsHumansMaleFemaleAdultMiddle AgedCrohn DiseaseBiological FactorsInflammatory Bowel DiseasesColitis, UlcerativeBiological TherapyProspective StudiesPhenotype

Stichwörter der Autor:innen

biologicalsfamilial historyinflammatory bowel diseasesurgery

Substanzen

Immunosuppressive AgentsBiological Factors

Autor:innen und Institutionen

  • H. Santa Creu i Sant Pau (Gastroenterology Department, Barcelona, Spain).
  • Departament de Medicina, Universitat Autònoma de Barcelona (Barcelona, Spain).
  • H. Universitari Germans Trias i Pujol (Gastroenterology Department, Badalona, Spain) and CIBEREHD (Madrid, Spain).
  • H. de La Princesa (Gastroenterology Department, Madrid) and Instituto de Investigación Sanitaria Princesa (IIS-IP, Madrid, Spain), Universidad Autónoma de Madrid (UAM, Madrid, Spain) and CIBEREHD (Madrid, Spain).
  • H. Universitario Reina Sofía (Gastroenterology Department, Córdoba, Spain).
  • H.Clínico Valencia (Gastroenterology Department, Valencia, Spain).

ORCID-Profile: Carlos González-Muñoza, Eugeni Domènech

Förderung

  • AbbVie
  • Galápagos
  • Janssen
  • Biogen
  • Takeda
  • Pfizer

Zitieren

APA

González-Muñoza, C., Calafat, M., Gisbert, J. P., Iglesias, E., Mínguez, M., Sicilia, B., Aceituno, M., Gomollón, F., Calvet, X., Ricart, E., De Castro, L., Rivero, M., Mesonero, F., Márquez, L., Nos, P., Rodríguez-Pescador, A., Guardiola, J., García-Sepulcre, M., García-López, S., …, & ENEIDA project of GETECCU (2024). Influence of familial forms of inflammatory bowel disease on the use of immunosuppressants, biological agents, and surgery in the era of biological therapies. Results from the ENEIDA project. Postgraduate Medical Journal. https://doi.org/10.1093/postmj/qgae076

Vancouver

González-Muñoza C, Calafat M, Gisbert JP, Iglesias E, Mínguez M, Sicilia B, et al. Influence of familial forms of inflammatory bowel disease on the use of immunosuppressants, biological agents, and surgery in the era of biological therapies. Results from the ENEIDA project. Postgraduate Medical Journal. 2024. doi:10.1093/postmj/qgae076

BibTeX
@article{GonzlezMuoza2024,
  author = {González-Muñoza, Carlos and Calafat, Margalida and Gisbert, Javier P and Iglesias, Eva and Mínguez, Miguel and Sicilia, Beatriz and Aceituno, Montserrat and Gomollón, Fernando and Calvet, Xavier and Ricart, Elena and De Castro, Luisa and Rivero, Montserrat and Mesonero, Francisco and Márquez, Lucía and Nos, Pilar and Rodríguez-Pescador, Ainhoa and Guardiola, Jordi and García-Sepulcre, MarianaFe and García-López, Santiago and Lorente-Poyatos, Rufo H and Alba, Cristina and Sánchez-Ocaña, Ramon and Vera, Isabel and Madero, Lucía and Riestra, Sabino and Navarro-Llavat, Mercedes and Pérez-Calle, Jose L and Camps, Blau and Van Domselaar, Manuel and Lucendo, Alfredo J and Martín-Arranz, Maria Dolores and Montoro-Huguet, Miguel A and Sierra-Ausín, Mónica and Llaó, Jordina and Carpio, Daniel and Varela, Pilar and Merino, Olga and Fernández-Salazar, Luis I and Piqueras, Marta and Sesé, Eva and Busquets, David and Tardillo, Carlos and Maroto, Nuria and Riera, Joan and Martínez-Flores, Carlos and Muñoz, Fernando and Gordillo-Ábalos, Jordi and Bertoletti, Federico and Garcia-Planella, Esther and Domènech, Eugeni and ENEIDA project of GETECCU, ENEIDA project of GETECCU},
  title = {Influence of familial forms of inflammatory bowel disease on the use of immunosuppressants, biological agents, and surgery in the era of biological therapies. Results from the ENEIDA project},
  journal = {Postgraduate Medical Journal},
  year = {2024},
  doi = {10.1093/postmj/qgae076}
}
Kostenlos starten →